India Bioeconomy
Kartavya Desk Staff
Syllabus: Biotechnology
Source: IE
Context: The India BioEconomy Report 2024, released by the Department of Biotechnology, highlighted that India’s bioeconomy crossed $165 billion, contributing 4.2% of GDP. It charts a roadmap to reach $300 billion by 2030 and $1 trillion by 2047.
Key Insights from India BioEconomy Report 2024:
• Rapid Market Growth: Bioeconomy doubled from $86 billion (2020) to $165 billion (2024), with projections of $1 trillion by 2047.
• Industrial & Pharma Dominance: 48% value came from industrial bioeconomy (biofuels, bioplastics); 35% from pharma, majorly vaccines.
• Start-up Surge: Number of companies grew from 5,365 in 2021 to 10,075 in 2024, expected to double again by 2030.
• Employment Potential: Projected to generate 35 million jobs by 2030 through biotech research, IT, and bio-manufacturing.
• Regional Disparities: 5 states (MH, KA, TG, GJ, AP) contribute two-thirds of total value; NE and Eastern India underperform (<6%).
• Fastest Growing Segment: Research & IT—including bioinformatics, clinical trials, and biotech software—is seeing the highest annual growth.
About India’s Achievements in Bioeconomy:
• Vaccine Revolution: India became a global leader in vaccine production post-COVID-19, boosting biotech infrastructure and innovation.
• Biofuel Expansion: Ethanol blending programs and fermentation-based fuel production have surged, reducing fossil fuel dependency.
• Global Recognition: India’s bioeconomy (4.2% of GDP) now compares well with US and China, although lagging behind EU nations like Spain (20%).
• Academic & Research Ecosystem: Premier institutes like IISc, NCBS, NIBMG have expanded biotech R&D.
• Digital Bio Solutions: AI-powered platforms for genome mapping, diagnostics, and precision farming are scaling rapidly.
Key Government Initiatives
• BioE3 Policy (2024): Launched to drive bio-based Economy, Environment, and Employment. Focus: biomanufacturing and research.
• National Bioeconomy Mission (Proposed): Suggested in the report to coordinate policy and funding under one umbrella.
• Single-Window Clearance: Recommended to ease biotech project approvals and remove regulatory delays.
• Startup Ecosystem Boost: Bio-incubators and funding support for biotech startups are growing under DBT’s BIRAC.
• Focus on Priority Areas: Marine biotech, functional foods, bioenzymes, space bio-research, and climate-resilient crops are key thrust zones.
Challenges in Indian Bioeconomy
• Regulatory Uncertainty: Delay in approval for GM crops hinders agricultural biotechnology despite proven productivity gains.
• Infrastructure Gaps: Labs and processing units in Eastern & NE India lack basic facilities and funding.
• Skilled Workforce Shortage: Need for biotech-ready manpower across domains like bioinformatics, fermentation tech, and IP law.
• Low Private Investment: Bioeconomy lags behind IT and pharma in attracting venture capital and FDI.
• Data and Standardization Issues: Lack of bioresource inventories and absence of quality assurance frameworks reduce export potential.
Measures & Way Forward:
• Enhance Policy Cohesion: Launch National Bioeconomy Mission for unified policy design, funding, and implementation.
• Promote GM Crop Adoption: Create evidence-based policies to approve safe GM varieties and improve yield outcomes.
• Address Regional Disparity: Incentivize biotech parks, PPPs, and academic-industry linkages in backward zones.
• Upskill Workforce: Establish training hubs in bioinformatics, synthetic biology, and AI in biotech.
• Scale Public-Private Partnerships: Collaborate with industries for R&D in clean bio-based technologies and scale global patents.
Conclusion:
India’s bioeconomy stands at a transformational juncture. With the right policy, infrastructure, and regulatory reforms, India can evolve into a global bio-manufacturing and innovation hub. Sustained efforts are vital to realize the vision of $1 trillion bioeconomy by 2047.
• Why is there so much activity in the field of biotechnology in our country? How has this activity benefitted the field of biopharma? (UPSC-2018)